Patents Assigned to Teligene Ltd.
  • Substituted quinolines useful as kinase inhibitors
    Patent number: 11427559
    Abstract: The present invention is directed to novel quinoline-3-carbonitriles according to Formula I, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities and are useful for the treatment of protein kinases mediated diseases and conditions.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: August 30, 2022
    Assignee: Teligene Ltd.
    Inventor: Dawei Zhang
  • Substituted pyrazolopyrimidines useful as kinases inhibitors
    Patent number: 11344553
    Abstract: The present disclosure is directed to novel pyrzaolopyrimidines, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present disclosure have protein kinases inhibitory activities and are expected to be useful for the treatment of protein kinases mediated diseases and conditions.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: May 31, 2022
    Assignee: Teligene Ltd.
    Inventor: Dawei Zhang
  • Maleate salts of (E)-N-(3-cyano-7-ethoxy-4-((4-phenoxyphenyl)amino) quinolin-6-yl)-4-(dimethylamino)but-2-enamide and crystalline forms thereof
    Patent number: 11034656
    Abstract: The present application relates to maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)aniline]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, crystalline forms thereof, to processes for its preparation, to pharmaceutical compositions comprising it and to its use in the control of disorders.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: June 15, 2021
    Assignee: Teligene Ltd.
    Inventor: Dawei Zhang
  • Pyridine compounds used as PI3 kinase inhibitors
    Patent number: 10173995
    Abstract: The present invention is directed to novel pyridines, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The present invention discloses compounds of Formulas I and II. The compounds and compositions of the present invention have protein kinases inhibitory activities and are expected to be useful for the treatment of protein kinases mediated diseases and conditions.
    Type: Grant
    Filed: January 11, 2014
    Date of Patent: January 8, 2019
    Assignee: Teligene Ltd.
    Inventor: Dawei Zhang
  • Substituted macrocycles useful as kinases inhibitors and methods of use thereof
    Patent number: 10159663
    Abstract: The present invention is directed to novel substituted macrocycles compounds, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities and are expected to be useful for the treatment of protein kinases mediated diseases and conditions.
    Type: Grant
    Filed: August 18, 2015
    Date of Patent: December 25, 2018
    Assignee: Teligene Ltd.
    Inventors: Xiaoyang Xia, Dawei Zhang
  • HETEROCYLCIC COMPOUNDS AS IDH2 INHIBITORS
    Publication number: 20180134683
    Abstract: The present invention is directed to novel heterocyclic compounds, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present invention have IDHs inhibitory activities and are useful for the treatment of Isocitrate dehydrogenases mediated diseases and conditions. Novel heterocyclic compounds disclosed herein include pyrimidines and triazines.
    Type: Application
    Filed: May 6, 2016
    Publication date: May 17, 2018
    Applicant: TELIGENE LTD.
    Inventors: Xiaoyang Xia, Dawei Zhang
  • SUBSTITUTED MACROCYCLES USEFUL AS KINASES INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20170216264
    Abstract: The present invention is directed to novel substituted macrocycles compounds, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities and are expected to be useful for the treatment of protein kinases mediated diseases and conditions.
    Type: Application
    Filed: August 18, 2015
    Publication date: August 3, 2017
    Applicant: TELIGENE LTD.
    Inventors: Xiaoyang Xia, Dawei Zhang
  • QUINAZOLINE DERIVATIVES AS KINASES INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20140235658
    Abstract: The present invention is directed to novel quinazolines, their derivatives, pharmaceutically acceptable salts, solvates, prodrug, stereoisomer, tautomer, metabolite and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities and are expected to be useful for the treatment of protein kinases mediated diseases and conditions.
    Type: Application
    Filed: October 12, 2012
    Publication date: August 21, 2014
    Applicant: Teligene Ltd.
    Inventor: Dawei Zhang